The Bio Report

Orbis Medicines is developing orally available synthetic macrocycles called ⁿCycles that can target diseases typically requiring biologic therapies, offering a novel alternative through its platform technology.

Base to Base Biotech by Jim Cornall

Orbis Medicines is revolutionizing macrocycle drug development by combining AI, big data, and high-throughput synthesis to make this complex class of molecules reliably designable and orally available for the first time.